Chemical formula: C₁₅H₁₄N₂O₄S  Molecular mass: 318.35 g/mol  PubChem compound: 6918638

Active ingredient description

Belinostat is a histone deacetylase (HDAC) inhibitor. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. It is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
L01XH04 L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XH Histone deacetylase (HDAC) inhibitors
Discover more medicines within L01XH04

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
BELEODAQ Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 414864-00-9
DrugBank Drug: DB05015
PubChem Compound: 6918638
RxNorm Ingredient: 1543543
SNOMED-CT Concept: 704194004
Belinostat (substance)
UNII Identifier: F4H96P17NZ


Belinostat is an active ingredient of these brands:

United States (US)

Brazil (BR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.